|
- LAIs Tied to Lower Relapse, Mortality Risk in Schizophrenia
Long-acting injectable antipsychotics are linked to a lower risk for disease relapse and mortality than oral antipsychotics in adults with schizophrenia, a new study shows
- Metoclopramide in the Treatment of Diabetic Gastroparesis
Acute Dystonic Reactions Acute dystonic reactions are the most frequent extrapyramidal side effects (EPS) from metoclopramide and typically occur within 24–48 h of initiating treatment, thus
- Untreated Tardive Dyskinesia Hinders Use of Antipsychotics
Tardive dyskinesia, often underdiagnosed and undertreated, hinders patient adherence to antipsychotics, affecting mental health treatment and caregivers #039; well-being, reports Dr Daniel Kremens
- Novel Drug Safe, Effective for Acute Schizophrenia - Medscape
The novel PDE10A inhibitor CPL #039;36 offers a new mechanism of action and is both safe and effective for acute exacerbations of schizophrenia, new research suggests
- Does Gabapentin Raise Dementia Risk? - Medscape
New data suggest an association between gabapentin for chronic back pain and increased risk of cognitive impairment, although experts urge caution in drawing any firm conclusions
- Treatment Considerations for Psychiatric Syndromes Associated with HIV . . .
Another important consideration is HIV-infected patients' increased sensitivity to antipsychotic-induced extrapyramidal symptoms, thought to be related to the damage to basal ganglia observed in
- Impressive New Data on Novel Schizophrenia Hopeful KarXT
The novel investigational antipsychotic KarXT was effective and well tolerated in adults with schizophrenia experiencing acute psychosis in a second phase 3 trial
- Long-Acting Injectables Curb Schizophrenia Readmission
Patients with schizophrenia discharged on an LAI antipsychotic had significantly lower 30-day psychiatric readmission rates than those sent home with an oral antipsychotic
|
|
|